secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001193125-23-143451
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical Q1 commercial revenue up 40% to $10.5M; reaffirms FY guidance; CCO resigns
--------------------------------------------------------------------------------

- Commercial revenue $10.5M (+40% YoY); total revenue $10.6M (+40%); gross margin 84% vs 76%.
- Net loss improved to $9.2M ($0.37/share) from $9.5M ($0.38); adjusted EBITDA loss flat at $6.4M.
- Cash $77.6M, no debt; reaffirms FY commercial revenue guidance of $49-51M; Q2 guidance $10.7-11.7M.
- Expects FDA approval for soft tissue repair and vitiligo in June 2023; RECELL GO submission by June 30.
- Erin Liberto resigned as CCO effective May 11; role discontinued. Promoted Bromley to SVP Global Sales, Garner to SVP Global Marketing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000119312523143451/0001193125-23-143451-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000119312523143451/d478946d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-143451

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer